The immunosuppressive drugs tocilizumab and sarilumab improved survival and recovery time of intensive care COVID-19 patients, according to a preprint.

From new treatments to an investigation into the virus’s origins, here are some of the developments we can expect this year.

Download this white paper from Collaborative Drug Discovery to explore how modern informatics systems like CDD Vault^® can provide a cross-domain platform for storage, analysis, and sharing to promote greater collaboration between drug discovery project team members.

The third FDA approval of an RNAi-based therapeutic marks the growing success of a technique that took two decades to get off the ground.

As COVID-19 therapies get emergency-use green lights, the Biden administration must organize a therapeutic review board to help identify what’s working and what’s not.

There are benefits of studying certain biological processes under microgravity, but whether those advantages outweigh the costs of getting experiments off Earth remains to be seen.

Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.

SARS-CoV-2, the virus that causes COVID-19, taps into human proteases such as furin to enter cells. Temporarily inhibiting those enzymes might stymie infection.

A recent study elucidates some of the changes that occur in the body after inoculation with a tuberculosis vaccine.